文献速递主动脉疾病

TEVAR与ANACONDA FEVAR联合应用的拉脱力评估及早期临床结果

Assessment of Pull-out Forces in TEVAR and ANACONDA FEVAR Combination and Early Clinical Results: Creation of a Proximal Landing Zone for FEVAR in Patients with Extent I and Extent IV TAAAs.
PubMed 文献 · Ann Vasc Surg · 2020-01-21

本研究评估了在不同胸主动脉支架内植入开窗Anaconda支架的稳定性,并回顾性分析了28例采用TEVAR/FEVAR联合技术治疗I型或IV型胸腹主动脉瘤的早期临床结果。体外拉脱力测试中位值为2.38 N至55.0 N,34-mm Anaconda支架在28-mm胸主动脉管状支架内稳定性最高;临床中25例(89.3%)动脉瘤成功治疗,平均随访15个月无支架连接失败或III型内漏。

要点

  • TEVAR联合FEVAR可为近端锚定区不足的I/IV型TAAA提供可行治疗选择。
  • 体外测试中,较厚Dacron膜的胸主动脉支架对Anaconda倒钩所致穿刺和撕裂的耐受性更好。
  • 临床队列30天再干预率28.6%,但无因联合技术失败所致。

核心结论

  • 胸主动脉管状支架联合开窗Anaconda支架是治疗近端锚定区不足的I型或IV型胸腹主动脉瘤的可行选择。

研究设计与样本

  • 体外实验测量开窗Anaconda支架植入不同厂商胸主动脉支架后的拉脱力,并在Instron拉伸试验机上施加连续增加的纵向拉力至100 N。

主要发现

  • 体外测试中位拉脱力范围为2.38 N至55.0 N,34-mm Anaconda支架在28-mm胸主动脉管状支架内稳定性最高。
  • 较薄Dacron材料或带聚四氟乙烯膜的支架易被Anaconda向下倒钩穿刺和撕裂。
  • 28例患者中25例(89.3%)动脉瘤成功治疗,30天再干预率为28.6%,但无因FEVAR/TEVAR联合失败所致。
  • 平均随访15个月,未观察到支架连接失败或膜损伤导致的III型内漏。

关键数值与推荐

  • 体外实验采用28-或30-mm胸主动脉管状支架,Anaconda支架 oversizing 至少2 mm(13.3-21.4),最小重叠15 mm。
  • 临床部分纳入28例患者,其中25例(89.3%)治疗成功,30天再干预率28.6%,平均随访15个月。

临床怎么用

  • 对于近端锚定区不足的I型或IV型TAAA,可考虑胸主动脉管状支架联合开窗Anaconda支架构建近端锚定区。
  • 选择胸主动脉支架时,较厚Dacron膜可能更耐受Anaconda倒钩所致的损伤。

局限性

  • 临床结果来自单中心回顾性分析,样本量有限。
  • 体外拉脱力测试不能完全模拟体内复杂受力环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although recent data on the treatment of thoracoabdominal aortic aneurysms (TAAAs) are promising, in some cases, the paravisceral segment of the aorta may not be suitable for a branched endograft due to space restrictions. A combination of a fenestrated aneurysm repair (FEVAR) with a thoracic aneurysm repair (TEVAR) may represent a feasible treatment option. The current investigation was performed to assess the stability of a fenestrated Anaconda device implanted into a set of thoracic endografts from different manufacturers. We then assessed our clinical results with the FEVAR/TEVAR combination. METHODS: Pull-out forces were measured in vitro after docking a fenestrated Anaconda graft within the distal end of different TEVAR devices. Anaconda devices were implanted in 28- or 30-mm thoracic tube grafts (oversizing of at least 2 mm: 13.3-21.4; minimum overlap of 15 mm). Continuously increasing longitudinal pull forces of up to 100 N were applied on an Instron Tensile Tester. Initial break point and damage to the endografts were documented. Clinical results of patients treated with such an FEVAR/TEVAR combination at our institution are presented as a second part of this study. RESULTS: Median pull-out forces ranged from 2.38 N to 55.0 N. The highest stability was achieved with 34-mm Anaconda devices in 28-mm thoracic tube grafts. Grafts with either thinner Dacron material or those featuring a polytetrafluorethylene membrane seemed especially vulnerable to punctures and tears caused by the downward-looking hooks of the Anaconda device. Between April 1, 2013 and December 31, 2018, in 28 of 172 patients treated with a fenestrated Anaconda device, prior implantation of a thoracic tube graft was necessary to create a sufficient proximal landing zone. In 25 cases (89.3%), the aneurysm was successfully treated. Although the 30-day reintervention rate in this subgroup was relatively high at 28.6%, none of these was due to a failure of the FEVAR/TEVAR combination. Upon an average follow-up of 15 months, no failure of the graft connection and no type III endoleak due to membrane damage were observed. CONCLUSIONS: The combination of a thoracic tube graft and a fenestrated Anaconda device is a viable option for the treatment of patients with Extent I or IV TAAAs with no adequate landing zone above the celiac trunk. Although pull-out testing has shown good stability with most assessed grafts, the thoracic devices with thicker Dacron membranes seemed to be especially suitable.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Falkensammer J, Taher F, Plimon M, et al. Assessment of Pull-out Forces in TEVAR and ANACONDA FEVAR Combination and Early Clinical Results: Creation of a Proximal Landing Zone for FEVAR in Patients with Extent I and Extent IV TAAAs. Ann Vasc Surg. 2020. PMID: 31978487. doi:10.1016/j.avsg.2020.01.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。